Organon reports FDA extension of target action date of review of Vtama sNDA
Organon (OGN) announced that the FDA extended by three months the target action date of its review of the supplemental New Drug Application, or ...
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial ...
Monthly Prescribing Reference8 小时
FDA Extends Review of Tapinarof Cream for Atopic Dermatitis
The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...
clinicaltrialsarena12 小时
Recent popularity of JAK inhibitors in atopic dermatitis
The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...
Organon: FDA Extends Vtama Atopic-Dermatitis Review to March
Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic ...
The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.
Zawya20 小时
After three successful events in the Kingdom, the Immunology Expo Forum is held for the ...
Under the auspices of the Saudi Society of Rheumatology, Saudi Society of Dermatology and Dermatologic Surgery, Saudi ...